Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.

Biochemical pharmacology - 1 Mar 2017

Heylen Elisabeth, Neyts Johan, Jochmans Dirk

Abstract excerpt

The development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV) infections is of great importance, especially considering the fact that RSV is one of the most important causes of pediatric respiratory infections. However, despite intense efforts, there is no antiviral or vaccine approved for the prevention or treatment of RSV infections. Several inhibitors, targeting different RSV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genome, Viral
Share to Receptors, Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Respiratory Syncytial Virus Infections

Share to Respiratory Syncytial Viruses

Share to Viral Proteins

Share to Virus Internalization

Share to Virus Replication

Source

Identifiers

PMID: 27659812
DOI: 10.1016/j.bcp.2016.09.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.PMID 27659812Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.Semantic proximity Read ↗

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604Semantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance ProfilesSemantic proximity Read ↗

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate modelSemantic proximity Read ↗

High-throughput screening of active compounds against human respiratory syncytial virusSemantic proximity Read ↗

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.Semantic proximity Read ↗

Antiviral drug synergy and mutational signatures in different epithelial cell models of RSV and hPIV infectionSemantic proximity Read ↗

Respiratory Syncytial Virus.Semantic proximity Read ↗

Characterization of a Respiratory Syncytial Virus L Protein InhibitorSemantic proximity Read ↗

MTOR Kinase is a Therapeutic Target for Respiratory Syncytial Virus and CoronavirusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.